MedTrace Logo

A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

NCT00741871 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2012-04-20

No results posted yet for this study

Summary

This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.

Conditions

  • Lymphoma, Malignant
  • Hodgkin's Lymphoma
  • B Cell Lymphoma

Interventions

DRUG

SB1518

SB1518 taken orally daily for 28 consecutive days in a 28 day cycle

Sponsors & Collaborators

  • S*BIO

    lead INDUSTRY

Principal Investigators

  • Anas Younes, M.D. · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741871 on ClinicalTrials.gov